UnknownPhase 2NCT00996385
Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma
Studying Malignant peritoneal mesothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Columbia University
- Principal Investigator
- Robert N Taub, MD, PhDColumbia University
- Intervention
- Velcade (bortezomib) plus Eloxatin (oxaliplatin)(drug)
- Enrollment
- 29 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2009 – 2014
Study locations (1)
- Columbia University Medical Center, New York, New York, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00996385 on ClinicalTrials.govOther trials for Malignant peritoneal mesothelioma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07330271PTC-Guided Therapy for Peritoneal MesotheliomaBeijing Tsinghua Chang Gung Hospital
- RECRUITINGPHASE2NCT06543069Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeMCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGNCT06581549Immune Microenvironment and Gene Expression Profiling in MesotheliomaIstituto Oncologico Veneto IRCCS
- RECRUITINGPHASE2NCT06057935A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal MesotheliomaMemorial Sloan Kettering Cancer Center